These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 8315425)

  • 1. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
    Antman K; Crowley J; Balcerzak SP; Rivkin SE; Weiss GR; Elias A; Natale RB; Cooper RM; Barlogie B; Trump DL
    J Clin Oncol; 1993 Jul; 11(7):1276-85. PubMed ID: 8315425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
    Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH
    J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
    Antman K; Crowley J; Balcerzak SP; Kempf RA; Weiss RB; Clamon GH; Baker LH
    Cancer; 1998 Apr; 82(7):1288-95. PubMed ID: 9529020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy of advanced sarcomas of bone and soft tissue.
    Antman KH
    Semin Oncol; 1992 Dec; 19(6 Suppl 12):13-20. PubMed ID: 1485169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
    Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Santoro A; Tursz T; Mouridsen H; Verweij J; Steward W; Somers R; Buesa J; Casali P; Spooner D; Rankin E
    J Clin Oncol; 1995 Jul; 13(7):1537-45. PubMed ID: 7602342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dana-Farber Cancer Institute studies in advanced sarcoma.
    Antman KH; Elias A
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):7-15. PubMed ID: 2106162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
    Maurel J; López-Pousa A; de Las Peñas R; Fra J; Martín J; Cruz J; Casado A; Poveda A; Martínez-Trufero J; Balañá C; Gómez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubió J; Andrés R; Sevilla I; de la Cruz JJ; Del Muro XG; Buesa JM
    J Clin Oncol; 2009 Apr; 27(11):1893-8. PubMed ID: 19273704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Edmonson JH; Ryan LM; Blum RH; Brooks JS; Shiraki M; Frytak S; Parkinson DR
    J Clin Oncol; 1993 Jul; 11(7):1269-75. PubMed ID: 8315424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
    J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide.
    Weh HJ; Agarwal K; Zornig C; Schwarz R; Dietel M; Hossfeld DK
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S189-93. PubMed ID: 8453696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
    Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer HJ; Van Hoesel Q; Blay JY; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J
    J Clin Oncol; 2000 Jul; 18(14):2676-84. PubMed ID: 10894866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study.
    Elias AD; Antman KH
    Cancer Treat Rep; 1986 Jul; 70(7):827-33. PubMed ID: 3087617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy of advanced soft-tissue sarcomas.
    Antman KH; Elias AD
    Semin Surg Oncol; 1988; 4(1):53-8. PubMed ID: 3281212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK).
    Leyvraz S; Bacchi M; Cerny T; Lissoni A; Sessa C; Bressoud A; Hermann R
    Ann Oncol; 1998 Aug; 9(8):877-84. PubMed ID: 9789611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide.
    Weh HJ; Zügel M; Wingberg D; Schwarz R; Zornig C; Dietel M; Hossfeld DK
    Onkologie; 1990 Dec; 13(6):448-52. PubMed ID: 2128712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
    Pappo AS; Devidas M; Jenkins J; Rao B; Marcus R; Thomas P; Gebhardt M; Pratt C; Grier HE
    J Clin Oncol; 2005 Jun; 23(18):4031-8. PubMed ID: 15767644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Soft tissue sarcoma: postoperative chemotherapy].
    Goto T; Kosaku H; Kobayashi H; Hozumi T; Kondo T
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1324-30. PubMed ID: 15446551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II evaluation of doxorubicin, ifosfamide, and dacarbazine plus amphotericin B in the treatment of metastatic soft tissue sarcomas. A pilot study.
    González-Manzano R; Vieitez JM; Tangco E; Fernandez de Alava E; Herranz P; Garcia-Foncillas J
    Am J Clin Oncol; 1993 Aug; 16(4):332-7. PubMed ID: 8328412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group.
    Blum RH; Edmonson J; Ryan L; Pelletier L
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S238-40. PubMed ID: 8453706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.